EXPERT: EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

Time from randomisation to the date of local or regional recurrence as a site of first recurrence.

Time from randomisation to the date of distant recurrence, regardless of occurrence of any intervening local or regional recurrence, contralateral breast cancer or second (non-breast) primary invasive cancer.

Time from randomisation to date of first evidence of local (invasive breast carcinoma or DCIS), regional or distanct recurrence; contralateral breast cancer (invasive breast carcinoma or DCIS); second (non-breast) primary invasive cancer; or death.

Time from randomisation to date of first evidence of local (invasive breast carcinoma), regional or distanct recurrence; contralateral breast cancer (invasive breast carcinoma); second (non-breast) primary invasive cancer; or death.

Time from randomisation to the date of local, regional or distant recurrence as a site of first recurrence.

Time from randomisation to date of death from any cause.

Time from randomisation to the receipt of salvage RT or mastectomy, individually and in combination (one or the other) as a composite endpoint.

Adverse events during treatment (up to 5 years of endocrine therapy) assessed using NCI CTCAE v4.0.

FACT-ES measure of endocrine symptoms.